	Dublin, Ireland-based biopharmaceutical company Allergan announced on Jan. 7, 2019 that it will establish an R&D presence in the Kendall Square section of Cambridge, MA.

	The site will be led by Don Frail, PhD, senior vice-president of Research and External Scientific Innovation and Non-Clinical and Translational Sciences. The company states that its R&D model, Open Science, incorporates partnering with biotech companies, academia, and other pharmaceutical companies to broaden its pipeline. The Cambridge site joins the company’s other US-based R&D sites in Madison, NJ, and San Francisco, CA.

	"One of the driving sources of innovation today comes from smaller biotechnology and pharma companies. Our new, strategic presence in Kendall Square will allow us to more easily interact and engage with venture firms and startups in the area," said David Nicholson, executive vice-president and chief R&D officer, in a company press release. "I am confident that our new location in Cambridge will accelerate the evaluation of scientific opportunities and further deliver on our Open Science model and the next wave of potentially transformational medicines."

	The company focuses on developing, manufacturing, and commercializing pharmaceutical, device, biologic, surgical, and regenerative medicine products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutics.

Bio/Pharma News

PharmTech Europe News

PharmTech News

Pharmaceutical Technology\'s In the Lab eNewsletter-02-06-2019

Dublin, Ireland-based biopharmaceutical company Allergan will establish an R&D presence in Cambridge, MA.